Amphora Discovery Corp.
www.amphoracorp.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amphora Discovery Corp.
Forest falls flat as Lexapro sales falter
Forest Laboratories' revenues fell flat in the third quarter of its fiscal year 2009 as sales of its lead product Lexapro declined significantly.
Investing in Hard Times
VCs worried about depressed financial markets and demanding Big Pharma customers are being tough on almost all start-ups seeking funding-but no tougher than on their existing portfolio companies. For some, hard times are creating opportunities. The circumstances of companies that raised money in the past few years are impacting newer firms now. Even organizations that met their milestones have seen valuations plummet, and are struggling to get financing. The down market is making it more desirable and easier for VCs to invest in late-stage start-ups. In-licensing has been popular, but investors are increasingly seeking value-priced components to fill out existing firms or launch new ones. Investors haven't stopped doing early-stage deals, but they're looking for firms with advantages that can reduce risk or cost, or speed a company to market. Drugmakers that used to sign big-money deals are now demanding that start-ups prove their technologies' merits through short-term, inexpensive pilot programs. Some firms aren't so pressed by hard times. VCs are promising stellar founders lots of support and time to take big risks they bet will pay off handsomely.
Meet the Market, As It Is: Amphora Emphasizes Risk Reduction
There are many ways start-ups can lower the risks of doing business in the current climate. Amphora's approach will likely include working for hire to cool cash burn while building relationships with skittish clients; leveraging assets that have ripened beyond the research phase; and helping customers reduce the risks they confront.
Selected Start-Ups (11/01)
In Vivo briefly summarizes the technologies of these recently founded companies: Amphora Discovery Corp., Aptamera Inc., DxS Ltd., Fossa Industries Inc., Medgenics Inc. and Molecular SkinCare Ltd.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice